NEPTUNE Match Study for Kidney Conditions

The NEPTUNE Match study is for children and adults (ages 1 to 80) who are already part of the NEPTUNE observational study. This study aims to help patients with kidney conditions like Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, and Membranous Nephropathy find clinical trials that might be a good fit for them. A team will translate findings from a Molecular Nephrology Board to inform you about potential trial matches. Success will be measured by how many matched participants receive an assessment and how well the communication methods work. Kidney health will also be tracked for up to 60 months.

Study design
This is an open-label study, meaning both you and your doctors will know about the treatments. It plans to enroll 375 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your kidney health will be tracked for up to 60 months, depending on the specific trial you might join.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04571658

NEPTUNE Match Study

Recruiting
NAAges 1–80Interventional
University of Michigan
~375 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Communication

At a glance

Recruiting sites
15 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Matched participants with at least one clinical trial receive a MNB assessment
Measured over 0-4 weeks
+2 more outcomes measured
Nephrotic Syndrome in Children
Focal Segmental Glomerulosclerosis
Minimal Change Disease
Minimal Change Nephrotic Syndrome
Membranous Nephropathy
FSGS
MCD
MCD - Minimal Change Disease
Alport Syndrome
16 sites across 12 states
Washington3
New York2
Pennsylvania2
Georgia1
Illinois1
Kansas1
Maryland1
Michigan1
  • Matthias Kretzler, MD · PRINCIPAL_INVESTIGATOR · University of Michigan

Opens a ready-to-send draft in your own email app — review before sending.

  • Matched participants with at least one clinical trial receive a MNB assessment0-4 weeks

    Proportion of NEPTUNE Match participants with at least one matching clinical trial, defined as receiving a Molecular Nephrology Board (MNB) assessment that provides a match to at least one targeted therapy in an ongoing clinical trial

  • Efficacy of communication methods at time of communication visit, measured by Teach Back 1 summary score12 weeks

    Key findings from MNB trial matching analyses and deliberations will be conveyed to study participants using a NEPTUNE Match Report that summarizes the findings. The report indicates the strength of matching to ongoing clinical trials and the uncertainty and research origins of the information. A sample Match Report can be found in Appendix C. The report will not contain individual data elements reviewed by the MNB. The creation of NEPTUNE Match Reports will follow health education principles including matching of content to patients' informational needs and health literacy levels, use of visual aids to clarify meaning of information, and avoidance of information overload of the participant.

  • Kidney health endpoints that are specific to each individual trial0-60 months

    The analytic integration supporting the Molecular Nephrology Board (MNB) case review will be initiated and will occur. The MNB will conduct the discussion and generate the integrated data summary and case report inclusive of clinical trial matching by webinar. Input from the MNB will be used to generate a final version of the participant NEPTUNE Match Report. This is a longitudinal outcome that will be assessed at the end of the study relative to endpoints specific to matched clinical trials, assessing the superiority of stratification (matching or alignment of patient molecular profiles to targeted therapies in clinical trials) to non-stratification.